SPRYD7

Across TCGA pan-cancer cohorts, SPRYD7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPRYD7 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SPRYD7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPRYD7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, ESCA, and ACC are the cancer types where SPRYD7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.076	0.553	.002	24	view →
ESCA	OS	Median	II,III,IV	0.109	0.931	<.001	24	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
UCEC	DFS	Median	All	1.000	0.636	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPRYD7–LIHC (DFS)

Open the LIHC breakdown →